Introduction
Acquired resistance is a concern with respect to two of the major antibiotics used in regimens to eradicate H pylori, metronidazole and clarithromycin. 1 Resistance is defined by a cut oV value, which depends on the minimum inhibitory concentration (MIC) of the strains and on the concentration of antibiotic that can be achieved in the tissue by a given therapeutic dose. Resistance to antibiotics is considered to be a major cause of failure in the treatment of bacterial infections in general and H pylori infection in particular. However, the clinical relevance of this concept has been challenged because resistance to clarithromycin is rare and resistance to metronidazole seems to be variable. We will review the data published in clinical trials in which the susceptibility of primary isolates has been determined.
Consequences of resistance to metronidazole

LIMITS OF THE METHODS USED TO DETERMINE METRONIDAZOLE RESISTANCE
Numerous methods have been used to determine metronidazole susceptibility or resistance of H pylori, 1 and there is no standardisation. The correlation between these diVerent methods is usually poor and raises the question of which are "true" results. Since the agar dilution method is the reference method for other bacteria, we think that it should also be used as the reference method for H pylori.
Another important point is the relative lack of reproducibility for a given method. Cederbrant et al introduced the concept that the redox potential may influence the result. 2 Indeed this parameter is usually not controlled and therefore may account for this lack of reproducibility.
These problems may explain the variability found in metronidazole resistance in H pylori, for which the molecular mechanism is not yet known.
There is cross resistance between metronidazole and tinidazole, the other metronidazole sometimes used.
METRONIDAZOLE RESISTANCE IN DUAL THERAPIES
Metronidazole has been used with bismuth salts, amoxycillin, and clarithromycin for treatment periods of one or two weeks. In dual therapies that combine bismuth salts and metronidazole, eradication rates range from 75 to 91% for susceptible strains and from only 16 to 22% for resistant strains [3] [4] [5] except in one study (87 v 72% respectively). 6 When a combination of amoxycillin and tinidazole was given for seven days in the study by Glupczynski et al, 7 none of the 13 metronidazole resistant strains was eradicated. Using the same dual therapy but with metronidazole instead of tinidazole and a treatment period of 10 days instead of seven, the same authors succeeded in eradicating 21 of 22 metronidazole susceptible strains but only two of eight metronidazole resistant strains. 8 With clarithromycin, Bazzoli et al found a rate of eradication of 60% in metronidazole susceptible strains and 30% in resistant strains. 9 In the MACH2 study, 10 better results were obtained but there was still a significant diVerence between metronidazole susceptible (86%) and metronidazole resistant (43%) strains.
METRONIDAZOLE RESISTANCE IN "STANDARD" TRIPLE THERAPIES
Regardless of the antibiotic given with metronidazole, either amoxycillin or tetracycline, and regardless of the duration of treatment, significant diVerences in eradication rates were found between susceptible and resistant strains (table 1) .
When the duration of treatment was decreased to four days, Glupczynski et al still obtained a cure rate of 47-60% for susceptible strains while none of the resistant strains was eradicated. 8 Only the results of Lynch et al, 17 who gave the regimen five times daily, and those of Lerang et al 18 14 using a triple therapy for seven days, obtained better results on metronidazole resistant strains than when they gave it for 14 days.
When ranitidine was used instead of a proton pump inhibitor (PPI), the eradication rate decreased from 95 to 83% for metronidazole susceptible strains and from 40 to 16% for metronidazole resistant strains.
METRONIDAZOLE RESISTANCE IN ANTISECRETORY DRUG BASED TRIPLE THERAPIES WITH
CLARITHROMYCIN
As shown in table 3, in six of eight studies performed there was a significant diVerence between the cure rate obtained with metronidazole susceptible (88-100%) and resistant strains (48-82%). However, only one study reported a low cure rate (48%) with a metronidazole resistant strain, the others producing a cure rate of 75% or more. Moayyedi et al 28 and Lerang et al 22 did not obtain diVerent eradication rates for the two groups.
More recently, in a German multicentre study using a pantoprazole based triple therapy in which 188 strains were cultured, the eradication rate fell from 90% when the strains were metronidazole susceptible to 74% when they were resistant. 30 Yousfi et al 31 were the only ones to use ranitidine in association with clarithromycin and metronidazole for 14 days, but no diVerence was observed between metronidazole resistant and susceptible strains (80 v 77%).
METRONIDAZOLE RESISTANCE IN QUADRUPLE
THERAPIES
Quadruple therapies-that is, standard triple therapies plus a PPI-have been proposed as the best eradication regimens to cure patients infected by resistant strains (table 4). de Boer et al 34 administered this treatment for four days to 54 patients. They cured 91% of their patients, 33% of those harbouring metronidazole resistant strains and 95% of those harbouring susceptible strains. When they increased the treatment period to seven days and used lansoprazole instead of omeprazole in 67 patients, the rates were 89 and 100% respectively. 37 Similar results were reported by Hosking et al. 41 
ERADICATION ACCORDING TO MIC VALUES
In the results presented, the strains were categorised as susceptible or resistant by the authors, but reference to the MIC was not always made. In a few studies, it is possible to look at the results according to the MIC. In a study by Xia et al, 26 who used a standard triple therapy on 121 patients, the eradication rates were 96% (MIC <4 mg/l), 62.5% (MIC 4-8 mg/l), and 53% (MIC >8 mg/l).
In a small number of cases, Moayyedi et al 28 obtained an eradication rate of 70% in metronidazole susceptible strains compared with 30% in resistant strains when the cut oV value for resistance was 32 mg/l, but they observed no diVerence when the disk diVusion method was used.
In two large multicentre studies, the MICs were determined by agar dilution in our laboratory and the cure rate expressed according to the MIC. 10 24 Despite the fact that in the study using amoxycillin, the treatment was given for 10 days instead of seven, there was a definite advantage to using the clarithromycin based triple therapy on metronidazole resistant strains.
In summary, the results observed are heterogeneous. However, there is a trend toward a lower success rate in metronidazole resistant strains. This trend becomes more marked in large studies, where MICs have been determined by the most accurate method. Clarithromycin is a better choice than amoxycillin as a second antibiotic.
Consequences of resistance to clarithromycin
DETECTION OF CLARITHROMYCIN RESISTANCE
The mechanism involved in clarithromycin resistance is now well known even at the molecular level. 42 When an H pylori strain is resistant to clarithromycin, there is a decrease in binding of the compound to ribosomes, and this is associated with a point mutation found on the 23S ribosomal RNA gene in one of two positions (2143 and 2144). 43 The consequence is a high level of resistance, which is therefore easy to detect phenotypically, whatever the method used. Furthermore, there are now molecular tests that can be applied after amplification of the 23S ribosomal RNA gene. Besides sequencing, polymerase chain reaction-restriction fragment length polymorphism and hybridisation have been used. 44 Cross resistance occurs between all macrolides, but clarithromycin resistance is rarely found, which limits the data available to evaluate its impact.
CLARITHROMYCIN RESISTANCE IN DUAL
THERAPIES
Only one study, the MACH2 study, has been performed to monitor possible H pylori resistance to dual therapies in which clarithromycin was combined with another antibiotic-for example, amoxycillin or metronidazole. In this study, only one strain was resistant to clarithromycin in the clarithromycin-amoxycillin group, and it was not eradicated, and three in the clarithromycin-metronidazole group, which were also not eradicated. 10 In dual therapies in which an antisecretory agent is given with clarithromycin for 14 days, early studies have shown a diVerence in the eradication rate between susceptible and resistant strains (table 5) , but the number of resistant strains was very low.
More recently, in a multicentre study in which the level of clarithromycin resistance was higher, there was a significant diVerence in the rate of eradication between clarithromycin susceptible strains (74%) and clarithromycin resistant strains (40%). In contrast, this diVerence did not exist when ranitidine-bismuth citrate was used instead of omeprazole (96 v 92%). 47 This result may be linked to the antimicrobial activity of bismuth, which acts In the first multicentre study performed, the ACT-10 study, 49 the combination omeprazoleamoxycillin-clarithromycin was given for 10 days. There were only six clarithromycin resistant strains, and only half were eradicated compared with 92% of clarithromycin susceptible strains (table 6 ). In contrast, in the MACH2 study the two clarithromycin resistant strains were eradicated.
A multicentre study, carried out in southwest France, evaluated pantoprazole instead of omeprazole. None of the five strains resistant to clarithromycin were eradicated compared with 86% of susceptible strains 50 (table 6) . Using the omeprazole-clarithromycinmetronidazole (OCM) combination, in the MACH2 study, four of six (67%) clarithromycin resistant strains were eradicated compared with 98 of 108 (91%) clarithromycin susceptible ones. 10 Current data are too scarce to draw definitive conclusions on the impact of clarithromycin resistance. However, the high level reported and the lack of reversibility suggest that it could become a major factor in treatment failure if its use increases in the future.
Conclusions
The impact of H pylori resistance to clarithromycin and metronidazole is not yet critical because the rate of resistance to clarithromycin is still limited and resistance to metronidazole can be partly overcome. Furthermore, by using a combination of the two antibiotics, one is still eVective when resistance to the other exists. However, it is of great importance to monitor this resistance and to find new active compounds for the treatment of H pylori infection as problems are already occurring when strains are resistant to both clarithromycin and metronidazole. 
